Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
Monday, June 1, 2009 - 08:42
in Health & Medicine
ORLANDO - When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.
Read the whole article on Science Blog
More from Science Blog
Related
- Vandetanib shows clinical benefit when combined with docetaxel for lung cancerMon, 1 Jun 2009, 9:44:28 EDT
- Novel 4-drug combination proves safe for lung cancer treatmentThu, 13 Nov 2008, 10:30:54 EST
- Study shows drug combination improves outcome for advanced non-small cell lung cancerSat, 30 May 2009, 11:29:37 EDT
- Iressa proves just as effective as chemotherapy for lung cancerThu, 20 Nov 2008, 19:32:03 EST
- Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patientsThu, 13 Nov 2008, 10:51:01 EST